Rxivist logo

Sickle Cell Disease (SCD), one of the world's most common genetic disorders, causes anemia and progressive multiorgan damage that typically shortens lifespan by decades; currently there is no broadly applicable curative therapy. Here we show that Cas9 RNP-mediated gene editing with an ssDNA oligonucleotide donor yields more than 20% correction of the sickle mutation in long-term engrafting human HSCs. Using RNA-seq, we further find that in vivo erythroid differentiation markedly enriches for cells carrying corrected β-globin alleles. Adoption of a high-fidelity Cas9 variant demonstrates that this approach can yield efficient editing with almost no off-target events. These findings indicate that the sickle mutation can be corrected in human HSCs at levels that are likely to be curative if translated into a therapy.

Download data

  • Downloaded 2,574 times
  • Download rankings, all-time:
    • Site-wide: 6,533
    • In genetics: 270
  • Year to date:
    • Site-wide: 18,559
  • Since beginning of last month:
    • Site-wide: 32,675

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide